Stuart J. Ince, PhD, joined Accent Therapeutics in July 2023 as Vice President, Program Leadership & Operations to drive Accent’s developing portfolio through clinical development, bringing over 20 years of experience in Research and Development. He was formerly Vice President of Program Management at Tango Therapeutics, and before that held Program Leader and Program Management roles on development programs for Bayer AG’s oncology portfolio. Stuart’s research contributed to transitioning multiple programs into development, and he holds 12 issued US patents. As a drug developer, he has brought multiple investigational new drugs into human clinical trials, in both solid and liquid tumor indications. He held a key role in the approval of Vitrakvi™ (larotrectinib) as the first drug to receive tissue agnostic approval as initial indication in the US, Europe, and China, gaining a unique perspective into the development of precision medicine for oncology. Stuart received his doctorate in organic chemistry from the University of Cambridge, UK, and was a Marie-Curie post-doctoral fellow at the RWTH in Aachen, Germany.